Jesus Delgado-Calle, PhD
Assistant Research Professor of Medicine
2016-present: Assistant Research Professor. Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
2016 ASBMR Most Outstanding Translational Abstract Award
2016 Best Basic Research presentation. Richard L. Roudebush VAMC Hospital.
2015 American Society of Hematology Scholar Award.
2015 American Society of Bone and Mineral Research Young Investigator Award.
2015 ASBMR/Sun Valley workshop Harold M. Frost Young Investigator Award.
2015 Best Translational presentation. Melvin and Bren Simon Cancer Center Research.
2015 Best Translational Research presentation. Richard L. Roudebush VAMC Hospital.
2015 ASBMR John Haddad Young Investigator Award.
2014 American Society of Hematology Abstract Achievement Award.
2013 Sevgi & Gideon Rodan Fellowship. International Bone & Mineral Society (IBMS).
2013 ASBMR Young Investigator Travel Grant for the ASBMR annual meeting.
2013 Travel award for the Seventh Fellows Forum on Metabolic Bone Diseases.
2012 Best oral basic communication award in the XVI Annual SEIOMM meeting.
2012 SEIOMM travel award for the ASBMR annual meeting.
2012 Young Investigator Award. Dutch Society for Calcium and Bone Metabolism.
2011 SEIOMM travel award for the ASBMR annual meeting.
2011 ECTS travel award for the 3rd Joint Meeting of the ECTS-IBMS.
R3 C310 HEMO
Osteocytes are the most abundant cells in bone and are considered as master regulators of bone homeostasis. My research focuses on the mechanisms by which osteocytes contribute to generate a microenvironment that is conducive to tumor progression, bone destruction and muscle weakness in multiple myeloma disease. Current projects investigate the effects of genetic and pharmacological inhibition of osteocyte-derived factors (i.e Sclerostin, Rankl) in tumor growth and multiple myeloma-induced bone fragility and muscle weakness; the role of bidirectional Notch signaling between MM cells and osteocytes in multiple myeloma disease; and the effects of Aplidin (a novel anti-tumor drug that targets eEF1A2), alone or in combination with other anti-tumor drugs, on bone cells and tumor progression. I also collaborate in studies examining the role of osteocytes in multiple myeloma-induced bone pain; the regulation of the skeletal actions of parathyroid hormone; and the deleterious effects that glucocorticoids have in the skeleton.
List of Current Research Projects
Targeting Notch in Multiple Myeloma. (American Society of Hematology Scholar Award). The goal of this proposal is to examine the effects of genetic and pharmacologic inhibition of Notch signaling on MM cell growth and MM-induced bone disease.
Characterization of Aplidin® (plitidepsin) effects on multiple myeloma (MM)-induced bone disease. (PharmaMar S.A). The goal of the current proposal is to examine the effects of Aplidin®, alone or in combination with glucocorticoid (GC) therapy, on the function of bone cells using in vitro, ex vivo and in vivo approaches.
American Society for biochemistry and Molecular biology
American Society of Hematology
American Society of Bone and Mineral Research
European Calcified Tissue Society
International Society of Bone and Mineral Research
Spanish Society of Bone Research and Mineral Metabolism